



(To be generally implemented in the Conditions of Contest)

## **World Bridge Federation “WBF” Anti-Doping Regulations**

### **1. Preamble**

- 1.1. The World Bridge Federation, a Recognized Federation by the International Olympic Committee, has accepted the World Anti-Doping code (“the Code”) and is applicable to the WBF. In accordance with the World Anti-Doping Program the WBF is also following the International Standards as they are laid down by the World Anti-Doping Agency (WADA).

### **2. Anti-doping Testing Events**

- 2.1. In specified International events which are all World Championships the WBF will test individual Competitors who are obliged to accept being tested.

### **3. Testing**

- 3.1. The WBF can plan and implement out-of competition tests.
- 3.2. The WBF can establish a Registered Testing Pool for International-level competitors and conduct in-competition and/or out-of-competition testing on the Registered Testing Pool.
- 3.3. The WBF can conduct Target Testing.
- 3.4. All testing being done by the WBF shall be conducted in conformity with the international standard for testing.

### **4. The prohibited list**

- 4.1. These Anti-Doping regulations incorporate the Prohibited List which is published and revised by WADA as described in Article 4.1. of the Code. The WBF will make the current Prohibited list available to each National

Bridge Organization (NBO), and each NBO shall ensure that the current Prohibited List is available to its members and constituents. <sup>1</sup>

## **5. Testing Proceedings**

- 5.1. The testing will normally be In-Competition testing - which is a test where 0a Competitor is selected for testing during a competition - with no advance notice. The analyses will be done by WADA accredited laboratories.
- 5.2. Testing will normally be done on a random basis at the site of the competition.
- 5.3. The handling of anti-doping matters is done by the WBF Anti-Doping Commission and the WBF Medical Commission.
- 5.4. How, when, where, who and how many will be tested is decided by the WBF Executive Council.

## **6. Therapeutic Use Exemptions (TUE)**

- 6.1. If a Competitor is undergoing medical treatment for a condition, which requires the taking of a substance on the Prohibited list, the Competitor must get a dispensation from the WBF Medical Commission.
- 6.2. The Competitor should contact his personal doctor or an accredited doctor in his/her own country asking him if it is possible to substitute the prohibited substance with an alternative substance not included in the prohibited list.
- 6.3. The doctor and the Competitor shall fill out a TUE standard application form (appendix 1) explaining why the Competitor is undergoing medical treatment with the substance mentioned in 6.1.
- 6.4. The application form is sent to the WBF Medical Commission and must be in the hands of the commission no less than 21 days before the competition in which the Competitor is playing commences.
- 6.5. If the Medical Commission gives dispensation, a medical certificate of approval for Therapeutic use (Appendix 2) will be issued in two parts. One will be given to the Competitor applying for dispensation and the Medical Commission will keep the other one until the end of the competition. After the competition is finished - and the Competitor has

---

<sup>1</sup> The Prohibited List in force is available on WADA's website at [www.wada-ama.org](http://www.wada-ama.org)

not been tested during the competition - the second part of the certificate will also be returned to the Competitor.

- 6.6. Issuing the medical certificate, the Medical Commission states its period of validity (depending on the nature of the illness).
- 6.7. If a Competitor just before the start of the competition is undergoing medical treatment with a substance on the Prohibited list, the Competitor has to present on site at the WBF Medical Commission the TUE standard application form to obtain, at the Commission's discretion, a dispensation.
- 6.8. In any case before using a substance on the prohibited list during the Championship a Competitor has to previously consult the WBF Medical Commission on site.
- 6.9. The work and the knowledge by the WBF Medical Commission concerning any individual is strictly confidential. No one outside the Medical Commission should have any knowledge of any case being dealt with by the Commission. All material received by the Medical Commission will be marked for destruction when the Medical Commission has decided on whether a dispensation can be given or not. The WBF Executive Council may receive statistical information from the WBF Medical Commission.

## **7. Results management for Tests Initiated by the WBF**

- 7.1. Results management for tests initiated by the WBF (including tests performed by WADA pursuant to agreement with the WBF) shall proceed as set forth below:
- 7.2. The results from all analyses must be sent to the WBF in encoded form, in a report signed by an authorized representative of the laboratory. All communication must be conducted in such a way that the results of analyses are confidential.
- 7.3. Upon receipt of an *A Sample Adverse Analytical Finding*, the WBF Anti-Doping Commission shall conduct a review to determine whether: (a) an applicable therapeutic use exemption has been granted, or (b) there is any apparent departure from *International Standards for Testing or Laboratory Analysis* that undermines the validity of the *Adverse Analytical Finding*.
- 7.4. If the initial review under Article 7.3. does not reveal an applicable therapeutic use exemption or departure from the *International Standard for Testing* or the *International Standard* for laboratory analysis in force at

the time of *Testing* or analysis that undermines the validity of the *Adverse Analytical Finding*, the WBF shall promptly notify the Competitor of: (a) the *Adverse Analytical Finding*; (b) the anti-doping rule violated, or, in a case under Articles 7.9 or 7.10, a description of the additional investigation that will be conducted as to whether there is an anti-doping rule violation; (c) the Competitors right to promptly request the analysis of the B *Sample* or, failing such request, that the B *Sample* analysis may be deemed waived; (d) the right of the Competitor and/or the Competitors representative to attend the B *Sample* opening and analysis if such analysis is requested; and (e) the Competitors right to request copies of the A and B *Sample* laboratory documentation package which includes information as required by the *International Standard* for Laboratory Analysis.

- 7.5. Arrangements shall be made for *Testing* the B *Sample* within three weeks of the notification described in Article 7.4. The Competitor may accept the A *Sample* analytical results by waiving the requirement for B *Sample* analysis. The WBF may nonetheless elect to proceed with the B *Sample* analysis.
- 7.6. The Competitor and/or his representative shall be allowed to be present at the analysis of the B *Sample*. Also a representative of the Competitors NBO as well as a representative of the WBF shall be allowed to be present.
- 7.7. If the B *Sample* proves negative, the entire test shall be considered negative and the Competitor, his NBO, and the WBF shall be so informed.
- 7.8. If a *Prohibited Substance* or the *Use of a Prohibited Method* is identified, the findings shall be reported to the Competitor, his NBO, the WBF, and to WADA.
- 7.9. The WBF Anti-Doping Commission shall conduct any follow-up investigation as may be required by the *Prohibited List*. Upon completion of such follow-up investigation, the WBF shall promptly notify the Competitor regarding the results of the follow-up investigation and whether or not the WBF asserts that an anti-doping rule was violated.
- 7.10. For apparent anti-doping rule violations that do not involve *Adverse Analytical Findings*, the WBF shall conduct any necessary follow-up investigation and shall then promptly notify the Competitor of the anti-doping rule, which appears to have been violated, and the basis of the violation.

- 7.11. If a Prohibited Substance or the use of a Prohibited Method is identified as described in Article 7.4. the competitor shall pay all costs related to the procedures and handling of the B sample analysis.

## 8. Right to a fair hearing

- 8.1. The WBF shall appoint a standing panel consisting of a Chair and 4 other experts with experience in anti-doping ("The WBF Doping Hearing Panel"). The Chair shall be a lawyer. Each panel member shall serve a term of four years.
- 8.2. When it appears, following the Results Management process described in Article 7, that these Anti-Doping Regulations have been violated in connection with the WBF's *Testing* at an *International Event* then the case shall be assigned to the WBF Doping Hearing Panel for adjudication.
- 8.3. The Chair of the WBF Doping Hearing Panel shall appoint three members from the panel (which may include the Chair) to hear each case. At least one appointed member shall be a lawyer. The appointed members shall have had no prior involvement with the case and shall not have the same nationality as the Competitor or other *Person* alleged to have violated these Anti-Doping Regulations.
- 8.4. Hearings pursuant to this Article shall be completed expeditiously following the completion of the results management process described in Article 7. Hearings held in connection with *Events* may be conducted on an expedited basis.
- 8.5. The NBO of the Competitor or other *Person* alleged to have violated these Anti-Doping Regulations may attend the hearing as an observer.
- 8.6. The WBF shall keep WADA fully apprised as to the status of pending cases and the result of all hearings.
- 8.7. A Competitor or other *Person* may forego a hearing by acknowledging the Anti-Doping Regulations violation and accepting *Consequences* consistent with the Code Articles 9 and 10 as proposed by the WBF.
- 8.8. The WBF Doping Hearing Panel decides on what costs shall be carried by the Competitor in connection with Article 7.11. and the Hearing.
- 8.9. Decisions of the WBF Doping Hearing Panel may be appealed to Court of Arbitration for Sport.

## 9. Sanctions

9.1. Concerning sanctions for violations, the WBF is, as stated above in section 1, following the Code.

9.2. The Competitors' attention is called to the Code Article 10.2:

First violation:	Two (2) years' ineligibility
Second violation:	Lifetime ineligibility

In addition the WBF will notify the Competitor's NBO with full details of the violation.

In accordance with the Code the player may be able to establish the basis for possibly eliminating or reducing any sanction.

9.3. In teams events where one Competitor of a team has been notified of a possible anti-doping rule violation the team may be subject to target testing. If more than one team Competitor is found to have committed an anti-doping rule violation during the event the team is disqualified.

9.4. If a Competitor refuses to be tested the refusal is regarded as an anti-doping rule violation and at least one more Competitor from the team may be randomly picked for immediate testing.

9.5. In pairs events, if one player is found to be positive for a restricted substance on the prohibited list following testing, the pair will be disqualified from any placement in the event, shall forfeit all medals or trophies won and each pair who finished behind this pair shall move up one position in the placement.

9.6. Because of the time delay in obtaining test results it is anticipated that a Competitor will often only be notified of a possible anti-doping violation after the competition has ended. In this event the WBF President may demand more testing being done of the Competitor's team. This Out-of-Competition testing - which is not In-Competition testing, ref. Art. 5.1 - shall be carried out by the Competitors NBO and at the NBO's expense in accordance with guidelines laid down by the WBF Anti-Doping Commission.